Machine-Learning Algorithm to Improve Cohort Identification in Interstitial Lung Disease.
Erica Farrand, Oksana Gologorskaya, Hunter Mills...
https://pubmed.ncbi.nlm.nih.gov/36943196/Actively Recruiting
Led by University of California, San Francisco · Updated on 2026-10-09
200
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying different combinations of remote monitoring devices to find the most feasible and acceptable way to detect important health events in people with Interstitial Lung Disease ILD. This study focuses on how well patients can use tools like home spirometry, pulse oximetry, weight scales, and electronic symptom questionnaires over a 12-month period. The goal is to improve how ILD care is delivered remotely by assessing adherence, retention, and data completeness. Participants will be randomly assigned to one of four groups using different combinations of monitoring devices. All participants will perform weekly home spirometry, while some will also measure oxygen levels daily, check their weight weekly, or do both depending on their group. They will complete brief electronic symptom questionnaires throughout the study. The study starts with an in-person baseline visit and ends with an in-person visit at 12 months. Remote follow-up visits at months 3, 6, and 9 will be held via Zoom. During the study, participants will regularly use electronic devices and complete questionnaires from home to track their lung health and symptoms. The research team will measure how often significant ILD events are detected, the time to first event detection, adherence to monitoring, retention in the study, and completeness of collected data. Quality of life, lung function changes, treatment adjustments, patient engagement, satisfaction, and costs related to home monitoring will also be assessed. The total study duration for each participant is 12 months.
CONDITIONS
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
E
Erica D Farrand, MD
Y
Yeji Lee
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Francisco
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Spirometer only | Spirometer + oximeter | Spirometer + scale | Spirometer + oximeter + scale | Usual clinic monitoring |
|---|---|---|---|---|---|
| What it is | Weekly home spirometry to measure lung function remotely | Weekly home spirometry plus daily pulse‑oximetry measurements | Weekly home spirometry together with weekly weight measurements | Remote monitoring using home spirometry, pulse‑oximetry and weight scale | In‑clinic pulmonary function tests every three to six months |
| Role in study design | One of four randomized home monitoring device combinations | Randomized arm combining spirometry and oxygen saturation monitoring | Randomized arm combining spirometry and weight measurement | Randomized arm using all three home monitoring devices | Current routine monitoring outside study |
| Purpose | Track lung function status remotely | Monitor both lung function and oxygen levels remotely | Assess lung function and weight changes remotely | Comprehensive remote physiologic tracking (lung function, oxygen saturation, weight) | Inform clinical status through periodic in‑person lung function testing |
| How it is performed | Patients complete spirometry maneuver weekly at home via device | Weekly home spirometry plus daily pulse‑oximetry readings at home | Weekly spirometry and weight measurements recorded via wireless scale | Combination of weekly spirometry, daily oximetry, and weekly weight via home devices | Pulmonary function tests conducted in clinic every three to six months |
| Evidence context | Home spirometry allows earlier and more frequent tracking than traditional clinic visits, with studies showing feasibility and correlation to lab measures | Combining spirometry with daily oximetry may enhance detection of disease changes beyond function alone | Adding weight monitoring may identify related physiologic changes, but clinical benefit remains uncertain | Comprehensive home monitoring may offer richer monitoring data; clinical impact still under investigation | Periodic in‑clinic PFTs remain the accepted method to assess ILD progression in practice |
| Important risks | Unsupervised home measurements may vary in quality and could miss acute changes | Same variability concerns plus potential misinterpretation of oximetry without clinical review | Weight data may vary with edema or scale positioning and not reflect disease status | Combining devices increases complexity and potential for data inconsistency | In‑clinic testing is supervised and standardized, reducing measurement error |
| Limitations | Requires consistent patient adherence and reliable device use | Adds daily device burden which may affect adherence over time | May not detect ILD progression based on weight alone | Complex protocol may affect use completeness and data reliability | Every‑few‑month testing may delay detection of rapid or acute changes |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 in-person baseline visit
Duration - 12 months
Participants use home spirometry weekly and may also use pulse oximetry daily and/or a wireless scale weekly depending on their group. They complete electronic symptom questionnaires and attend remote follow-up visits via Zoom at months 3, 6, and 9.
Remote visits at months 3, 6, and 9
Duration - 1 day
Participants complete a final visit at the UCSF Interstitial Lung Disease Clinic to conclude the study assessments.
1 in-person visit at month 12
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Erica Farrand, Oksana Gologorskaya, Hunter Mills...
https://pubmed.ncbi.nlm.nih.gov/36943196/Jin Ge, Valy Fontil, Sara Ackerman...
https://pubmed.ncbi.nlm.nih.gov/37611253/Joy P Ku, Ida Sim
https://pubmed.ncbi.nlm.nih.gov/33990671/Ida Sim
https://pubmed.ncbi.nlm.nih.gov/31483966/Marlies S Wijsenbeek, Catharina C Moor, Kerri A Johannson...
https://pubmed.ncbi.nlm.nih.gov/36206780/Anne-Marie Russell, Huzaifa Adamali, Philip L Molyneaux...
https://pubmed.ncbi.nlm.nih.gov/27089018/Margaret A Handley, Courtney R Lyles, Charles McCulloch...
https://pubmed.ncbi.nlm.nih.gov/29328873/Anobel Y Odisho, Andrew W Liu, Ali R Maiorano...
https://pubmed.ncbi.nlm.nih.gov/37031033/Jonathan Ilowite, Gita Lisker, Harly Greenberg
https://pubmed.ncbi.nlm.nih.gov/33590991/University of California, San Francisco
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor